Generic Medicine Info
Indications and Dosage
Intramuscular, Intravenous
Cerebrovascular disorders, Cognitive disorder, Head injury, Parkinson's disease
Adult: 500-1,000 mg daily given via IM inj or slow IV inj over 3-5 minutes, or infused at a rate of 40-60 drops/minute.

Cerebrovascular disorders, Cognitive disorder, Head injury, Parkinson's disease
Adult: As tab: 500 mg once daily or bid, or 1,000 mg once daily. As solution: 100-200 mg bid or tid.
May be taken with or without food.
Incompatible with meclofenoxate-containing products.
Hypertonia of the parasympathetic nervous system.
Special Precautions
Patients with persistent intracranial haemorrhage. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Bradycardia, tachycardia.
Gastrointestinal disorders: Diarrhoea, epigastric discomfort, stomach pain.
General disorders and admin site conditions: Fatigue.
Nervous system disorders: Dizziness, headache.
Skin and subcutaneous tissue disorders: Rashes.
Vascular disorders: Hypotension.
Drug Interactions
May potentiate the effect of levodopa.
Description: Citicoline is a naturally occurring endogenous nucleoside involved in the biosynthesis of lecithin. It increases the synthesis of phosphatidylcholine (main neuronal membrane phospholipid) and enhances acetylcholine production. It is also claimed that it increases blood flow and oxygen consumption in the brain.
Synonym: CDP-choline, cytidine diphosphate.
Absorption: Rapidly absorbed in the gastrointestinal tract. Bioavailability: >90%. Time to peak plasma concentration: 1 hour after oral administration followed by 2nd peak at 24 hours post-dosing.
Distribution: Distributed throughout the body, crosses blood-brain barrier.
Metabolism: Metabolised in the liver and gut wall via hydrolysis to choline and cytidine.
Excretion: Mainly via respiratory CO2 and urine. Elimination half-life: 71 hours (urine); 56 hours (respiratory CO2).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Citicoline, CID=13804, (accessed on Jan. 21, 2020)

Store below 30°C.
MIMS Class
Nootropics & Neurotonics/Neurotrophics
ATC Classification
N06BX06 - citicoline ; Belongs to the class of other psychostimulants and nootropics.
Anon. Citicoline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/02/2019.

Buckingham R (ed). Citicoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/02/2019.

Cholinerv (UNILAB, Inc.). MIMS Philippines. Accessed 30/01/2019 .

Disclaimer: This information is independently developed by MIMS based on Citicoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Brainact
  • Cholinerv
  • Ciaxon 500
  • Citico
  • Sancit 500
  • Sancit/Sancit 125/Sancit 250
  • Strocit
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in